Cybin Inc. CYBN announced that the World Intellectual Property Organization (WIPO) published an international patent application covering a range of inhalation delivery methods for psychedelic molecules.
“Our progress to secure IP for unique psychedelic delivery methods strongly aligns and supports our current CYB004 pipeline program of deuterated DMT via inhalation, which is aimed at overcoming some of the known challenges of oral and IV-administered DMT,” explained the company’s CEO, Doug Drysdale.
The Patent Cooperation Treaty published is called “Methods For Delivery Of Psychedelic Medications By Inhalation And Systems For Performing The Methods,” and Cybin expects that it will be a viable tool to protect currently in-development inhaled forms of psychedelic molecules.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.